Role of P63 MarkerinDifferentiation betweenBenign and Malignant Breast Tumors

Abstract

This is a descriptive retrospective study conducted at Radiation and Isotope Center at Khartoum (RICK) and Khartoum Teaching Hospital (Khartoum State) and Sudan university of science and technology, college of medical laboratory sciences during the period from February to July 2016, aimed to study the role of p63 in differentiation between benign and malignant breast tumors using immunohistochemistry. Forty paraffin blocks previously diagnosed as breast tumors were included in this study (30 (75%) of them were malignant samples and 10 (25%)of them were benign samples). The paraffin blocks were cut by rotary microtome, then stained by immunohistochemical method (dextran labeled polymer (Thermo -ultra vision) technique) for detection of p63.Patents data was analyzed using SPSS program version 11.5( Frequencies, mean and chi-square tests were calculated ). The age of patients ranged between 15 to 80 years with mean age of 41 years. The study revealed that most patients were less than 40 years representing 22 (55%) and the remaining 18 (45%) were more than 40 years. Regarding the histological subtype includes 27 (67.5%) samples invasive ductal carcinoma, 2 (5%) samples medullary carcinoma, 1 (2.5%) sample papillary carcinoma, 6 (15%) samples fibro adenoma and 4 (10%) samples fibrocystic change, the study revealed the most patient were diagnosed as invasive ductal carcinoma. The grade of tumor include 7 (23.3%) samples grade I , 11 (36.7%) samples grade II, 10 (33.3%) samples grade III and 2 (6.7%) samples not graded, most patients were found in grade II and III.

P63 expression showed positive result among benign breast tumors in 9/10 (22.5%) samples, while in malignant breast tumors gave positive expression in 6/30(15%) samples, this result showed significant statistic association (P.value 0.000). The study concluded that the p63 expression is associated with benign breast tumors.